News

China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...
Endpoints News1h
Keytru­da around head and neck can­cer surgery cuts chance of dis­ease com­ing back
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
Targeted Oncology15h
KEYNOTE-689 Trial of Pembrolizumab Shows Promising EFS in LA-HNSCC
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
The American Journal of Managed Care16h
Pembrolizumab Before, After Surgery Improves Head and Neck Cancer Outcomes: Ravindra Uppaluri, MD, PhD
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...